Scott Akamine - 01 Jun 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Chief Legal Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Jun 2021
Net transactions value
$0
Form type
4
Filing time
03 Jun 2021, 16:34:29 UTC
Previous filing
28 May 2021
Next filing
11 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +281,762 $0.000000 281,762 01 Jun 2021 Common Stock 281,762 $13.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.